# Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

> **NCT04460001** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Assiut University** · enrollment: 100 (estimated)

## Conditions studied

- Ophthalmopathy

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Ranibizumab
- **DRUG:** triamcinolone acetate

## Key facts

- **NCT ID:** NCT04460001
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-16
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460001, "Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04460001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*